<DOC>
	<DOCNO>NCT01301313</DOCNO>
	<brief_summary>To evaluate efficacy safety levosimendan versus conventional intensified inotropic treatment , critical child severe acute heart failure persist despite received conventional inotropic treatment .</brief_summary>
	<brief_title>Efficacy Safety Levosimendan Severe Acute Heart Failure Critical Children</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>Patients give write consent participate study transfer material cellular molecular study . Understand purpose study available perform procedure write protocol . Any child 1 day old 18 year old , admit Paediatric Intensive Care Unit due severe acute heart failure etiology . All patient express wish participate protocol hypertrophic restrictive cardiomyopathy aortic Stenosis know allergy drug use study possible prescribe study medication contraindicate accord Summary Product Characteristic accord criterion physician responsible patient pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Acute heart failure</keyword>
	<keyword>Children</keyword>
	<keyword>Levosimendan</keyword>
	<keyword>Inotropic treatment</keyword>
</DOC>